7.75  -0.05 (-0.64%)		05-22 16:00
Open: 7.8 High: 8.22 Volume: 39,261		Pre. Close: 7.8 Low: 7.6 Market Cap: 340(M)

Short term
Mid term
Targets	6-month :	9.6	1-year :	11.21
Resists	First :	8.22	Second :	9.6
Pivot price	7.05
Supports	First :	6.87	Second :	6.05
MAs	MA(5) :	7.7	MA(20) :	6.87
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	87.3	D(3) :	91.1
RSI	RSI(14): 62.4
52-week	High :	8.22	Low :	5.32

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NNNN ] has closed below upper band by 23.7%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	8.01 - 8.05	8.05 - 8.09
Low:	7.21 - 7.25	7.25 - 7.29
Close:	7.74 - 7.8	7.8 - 7.86

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Thu, 20 Feb 2025
Anbio Biotechnology Closes Initial Public Offering, Raising $8 Million on Nasdaq - Nasdaq

Thu, 20 Feb 2025
Fresh Biotech Player Enters Nasdaq: Will Anbio's $8M IPO Fuel Its Global Expansion? - Stock Titan

Wed, 19 Feb 2025
Anbio Biotechnology's IPO opens up 5% - Investing.com

Tue, 18 Feb 2025
NNNN - ANBIO BIOTECHNOLOGY Latest Stock News & Market Updates - Stock Titan

Tue, 18 Feb 2025
Medical Tech Pioneer Anbio Sets $8M IPO Launch: Strategic Expansion Plans Revealed - Stock Titan

Tue, 18 Feb 2025
Anbio Biotechnology Announces Pricing of Initial Public Offering - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	44 (M)
Shares Float	40 (M)
Held by Insiders	4.7 (%)
Held by Institutions	4.8 (%)
Shares Short	20 (K)
Shares Short P.Month	23 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.4
Profit Margin	28.9 %
Operating Margin	-68.7 %
Return on Assets (ttm)	7.1 %
Return on Equity (ttm)	14.8 %
Qtrly Rev. Growth	-36.1 %
Gross Profit (p.s.)	0.13
Sales Per Share	0.18
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	2 (M)
Levered Free Cash Flow	1 (M)

PE Ratio	152.6
PEG Ratio	0
Price to Book value	18.6
Price to Sales	40.88
Price to Cash Flow	161

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.